Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Molly Schwenn is active.

Publication


Featured researches published by Molly Schwenn.


Journal of the National Cancer Institute | 2009

A Case–Control Study of Smoking and Bladder Cancer Risk: Emergent Patterns Over Time

Dalsu Baris; Margaret R. Karagas; Castine Verrill; Alison Johnson; Angeline S. Andrew; Carmen J. Marsit; Molly Schwenn; Joanne S. Colt; Sai Cherala; Claudine Samanic; Richard Waddell; Kenneth P. Cantor; Alan R. Schned; Nathaniel Rothman; Jay H. Lubin; Joseph F. Fraumeni; Robert N. Hoover; Karl T. Kelsey; Debra T. Silverman

BACKGROUND Cigarette smoking is a well-established risk factor for bladder cancer. The effects of smoking duration, intensity (cigarettes per day), and total exposure (pack-years); smoking cessation; exposure to environmental tobacco smoke; and changes in the composition of tobacco and cigarette design over time on risk of bladder cancer are unclear. METHODS We examined bladder cancer risk in relation to smoking practices based on interview data from a large, population-based case-control study conducted in Maine, New Hampshire, and Vermont from 2001 to 2004 (N = 1170 urothelial carcinoma case patients and 1413 control subjects). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. To examine changes in smoking-induced bladder cancer risk over time, we compared odds ratios from New Hampshire residents in this study (305 case patients and 335 control subjects) with those from two case-control studies conducted in New Hampshire in 1994-1998 and in 1998-2001 (843 case patients and 1183 control subjects). RESULTS Regular and current cigarette smokers had higher risks of bladder cancer than never-smokers (for regular smokers, OR = 3.0, 95% CI = 2.4 to 3.6; for current smokers, OR = 5.2, 95% CI = 4.0 to 6.6). In New Hampshire, there was a statistically significant increasing trend in smoking-related bladder cancer risk over three consecutive periods (1994-1998, 1998-2001, and 2002-2004) among former smokers (OR = 1.4, 95% CI = 1.0 to 2.0; OR = 2.0, 95% CI = 1.4 to 2.9; and OR = 2.6, 95% CI = 1.7 to 4.0, respectively) and current smokers (OR = 2.9, 95% CI = 2.0 to 4.2; OR = 4.2, 95% CI = 2.8 to 6.3; OR = 5.5, 95% CI = 3.5 to 8.9, respectively) (P for homogeneity of trends over time periods = .04). We also observed that within categories of intensity, odds ratios increased approximately linearly with increasing pack-years smoked, but the slope of the increasing trend declined with increasing intensity. CONCLUSIONS Smoking-related risks of bladder cancer appear to have increased in New Hampshire since the mid-1990s. Based on our modeling of pack-years and intensity, smoking fewer cigarettes over a long time appears more harmful than smoking more cigarettes over a shorter time, for equal total pack-years of cigarettes smoked.


Human Molecular Genetics | 2011

A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3

Montserrat Garcia-Closas; Yuanqing Ye; Nathaniel Rothman; Jonine D. Figueroa; Núria Malats; Colin P. Dinney; Nilanjan Chatterjee; Ludmila Prokunina-Olsson; Zhaoming Wang; Jie Lin; Francisco X. Real; Kevin B. Jacobs; Dalsu Baris; Michael J. Thun; Immaculata De Vivo; Demetrius Albanes; Mark P. Purdue; Manolis Kogevinas; Ashish M. Kamat; Seth P. Lerner; H. Barton Grossman; Jian Gu; Xia Pu; Amy Hutchinson; Yi Ping Fu; Laurie Burdett; Meredith Yeager; Wei Tang; Adonina Tardón; Consol Serra

Genome-wide and candidate-gene association studies of bladder cancer have identified 10 susceptibility loci thus far. We conducted a meta-analysis of two previously published genome-wide scans (4501 cases and 6076 controls of European background) and followed up the most significant association signals [17 single nucleotide polymorphisms (SNPs) in 10 genomic regions] in 1382 cases and 2201 controls from four studies. A combined analysis adjusted for study center, age, sex, and smoking status identified a novel susceptibility locus that mapped to a region of 18q12.3, marked by rs7238033 (P = 8.7 × 10(-9); allelic odds ratio 1.20 with 95% CI: 1.13-1.28) and two highly correlated SNPs, rs10775480/rs10853535 (r(2)= 1.00; P = 8.9 × 10(-9); allelic odds ratio 1.16 with 95% CI: 1.10-1.22). The signal localizes to the solute carrier family 14 member 1 gene, SLC14A1, a urea transporter that regulates cellular osmotic pressure. In the kidney, SLC14A1 regulates urine volume and concentration whereas in erythrocytes it determines the Kidd blood groups. Our findings suggest that genetic variation in SLC14A1 could provide new etiological insights into bladder carcinogenesis.


Cancer Research | 2013

Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer

Montserrat Garcia-Closas; Nathaniel Rothman; Jonine D. Figueroa; Ludmila Prokunina-Olsson; Summer S. Han; Dalsu Baris; Eric J. Jacobs; Núria Malats; Immaculata De Vivo; Demetrius Albanes; Mark P. Purdue; Sapna Sharma; Yi Ping Fu; Manolis Kogevinas; Zhaoming Wang; Wei Tang; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R. Karagas; Alan R. Schned; Gerald L. Andriole; Robert L. Grubb; Amanda Black; Susan M. Gapstur; Michael J. Thun

Bladder cancer results from the combined effects of environmental and genetic factors, smoking being the strongest risk factor. Evaluating absolute risks resulting from the joint effects of smoking and genetic factors is critical to assess the public health relevance of genetic information. Analyses included up to 3,942 cases and 5,680 controls of European background in seven studies. We tested for multiplicative and additive interactions between smoking and 12 susceptibility loci, individually and combined as a polygenic risk score (PRS). Thirty-year absolute risks and risk differences by levels of the PRS were estimated for U.S. males aged 50 years. Six of 12 variants showed significant additive gene-environment interactions, most notably NAT2 (P = 7 × 10(-4)) and UGT1A6 (P = 8 × 10(-4)). The 30-year absolute risk of bladder cancer in U.S. males was 6.2% for all current smokers. This risk ranged from 2.9% for current smokers in the lowest quartile of the PRS to 9.9% for current smokers in the upper quartile. Risk difference estimates indicated that 8,200 cases would be prevented if elimination of smoking occurred in 100,000 men in the upper PRS quartile compared with 2,000 cases prevented by a similar effort in the lowest PRS quartile (P(additive) = 1 × 10(-4)). Thus, the potential impact of eliminating smoking on the number of bladder cancer cases prevented is larger for individuals at higher than lower genetic risk. Our findings could have implications for targeted prevention strategies. However, other smoking-related diseases, as well as practical and ethical considerations, need to be considered before any recommendations could be made.


Human Molecular Genetics | 2014

Genome-wide association study identifies multiple loci associated with bladder cancer risk

Jonine D. Figueroa; Yuanqing Ye; Afshan Siddiq; Montserrat Garcia-Closas; Nilanjan Chatterjee; Ludmila Prokunina-Olsson; Victoria K. Cortessis; Charles Kooperberg; Olivier Cussenot; Simone Benhamou; Jennifer Prescott; Stefano Porru; Colin P. Dinney; Núria Malats; Dalsu Baris; Mark P. Purdue; Eric J. Jacobs; Demetrius Albanes; Zhaoming Wang; Xiang Deng; Charles C. Chung; Wei Tang; H. Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Börje Ljungberg; Françoise Clavel-Chapelon; Elisabete Weiderpass; Vittorio Krogh; Miren Dorronsoro; Ruth C. Travis

Candidate gene and genome-wide association studies (GWAS) have identified 11 independent susceptibility loci associated with bladder cancer risk. To discover additional risk variants, we conducted a new GWAS of 2422 bladder cancer cases and 5751 controls, followed by a meta-analysis with two independently published bladder cancer GWAS, resulting in a combined analysis of 6911 cases and 11 814 controls of European descent. TaqMan genotyping of 13 promising single nucleotide polymorphisms with P < 1 × 10(-5) was pursued in a follow-up set of 801 cases and 1307 controls. Two new loci achieved genome-wide statistical significance: rs10936599 on 3q26.2 (P = 4.53 × 10(-9)) and rs907611 on 11p15.5 (P = 4.11 × 10(-8)). Two notable loci were also identified that approached genome-wide statistical significance: rs6104690 on 20p12.2 (P = 7.13 × 10(-7)) and rs4510656 on 6p22.3 (P = 6.98 × 10(-7)); these require further studies for confirmation. In conclusion, our study has identified new susceptibility alleles for bladder cancer risk that require fine-mapping and laboratory investigation, which could further understanding into the biological underpinnings of bladder carcinogenesis.


Human Molecular Genetics | 2012

Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer

Wei Tang; Yi-Ping Fu; Jonine D. Figueroa; Núria Malats; Montserrat Garcia-Closas; Nilanjan Chatterjee; Manolis Kogevinas; Dalsu Baris; Michael J. Thun; Jennifer L. Hall; Immaculata De Vivo; Demetrius Albanes; Patricia Porter-Gill; Mark P. Purdue; Laurie Burdett; Luyang Liu; Amy Hutchinson; Timothy Myers; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R. Karagas; Alan R. Schned; Amanda Black; Eric J. Jacobs; W. Ryan Diver

A recent genome-wide association study of bladder cancer identified the UGT1A gene cluster on chromosome 2q37.1 as a novel susceptibility locus. The UGT1A cluster encodes a family of UDP-glucuronosyltransferases (UGTs), which facilitate cellular detoxification and removal of aromatic amines. Bioactivated forms of aromatic amines found in tobacco smoke and industrial chemicals are the main risk factors for bladder cancer. The association within the UGT1A locus was detected by a single nucleotide polymorphism (SNP) rs11892031. Now, we performed detailed resequencing, imputation and genotyping in this region. We clarified the original genetic association detected by rs11892031 and identified an uncommon SNP rs17863783 that explained and strengthened the association in this region (allele frequency 0.014 in 4035 cases and 0.025 in 5284 controls, OR = 0.55, 95%CI = 0.44-0.69, P = 3.3 × 10(-7)). Rs17863783 is a synonymous coding variant Val209Val within the functional UGT1A6.1 splicing form, strongly expressed in the liver, kidney and bladder. We found the protective T allele of rs17863783 to be associated with increased mRNA expression of UGT1A6.1 in in-vitro exontrap assays and in human liver tissue samples. We suggest that rs17863783 may protect from bladder cancer by increasing the removal of carcinogens from bladder epithelium by the UGT1A6.1 protein. Our study shows an example of genetic and functional role of an uncommon protective genetic variant in a complex human disease, such as bladder cancer.


Pharmacogenetics and Genomics | 2010

A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background

Montserrat Garcia-Closas; David W. Hein; Debra T. Silverman; Núria Malats; Meredith Yeager; Kevin B. Jacobs; Mark A. Doll; Jonine D. Figueroa; Dalsu Baris; Molly Schwenn; Manolis Kogevinas; Alison Johnson; Nilanjan Chatterjee; Lee E. Moore; Timothy Moeller; Francisco X. Real; Stephen J. Chanock; Nathaniel Rothman

The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We reported earlier on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on seven single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3′ end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype. The agreement between the 7-SNP NAT2 inferred phenotype and the tag SNP, rs1495741, was initially assessed in 2174 individuals from the Spanish Bladder Cancer Study (SBCS), and confirmed in a subset of individuals from the Main and Vermont component the New England Bladder Cancer Study (NEBCS). We also investigated the association of rs1495741 genotypes with NAT2 catalytic activity in cryopreserved hepatocytes from 154 individuals of European background. We observed very strong agreement between rs1495741 and the 7-SNP inferred NAT2 phenotype: sensitivity and specificity for the NAT2 slow phenotype was 99 and 95%, respectively. Our findings were replicated in an independent population from the NEBCS. Estimates for the association between NAT2 slow phenotype and bladder cancer risk in the SBCS and its interaction with cigarette smoking were comparable for the 7-SNP inferred NAT2 phenotype and rs1495741. In addition, rs1495741 genotypes were strongly related to NAT2 activity measured in hepatocytes (P<0.0001). A novel NAT2 tag SNP (rs1495741) predicts with high accuracy the 7-SNP inferred NAT2 phenotype, and thus can be used as a sole marker in pharmacogenetic or epidemiological studies of populations of European background. These findings illustrate the utility of tag SNPs, often used in genome-wide association studies (GWAS), to identify novel phenotypic markers. Further studies are required to determine the functional implications of rs1495741 and the structure and evolution of the haplotype on which it resides.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk

Yi Ping Fu; Indu Kohaar; Nathaniel Rothman; Julie Earl; Jonine D. Figueroa; Yuanqing Ye; Núria Malats; Wei Tang; Luyang Liu; Montserrat Garcia-Closas; Brian Muchmore; Nilanjan Chatterjee; Mc Anthony Tarway; Manolis Kogevinas; Patricia Porter-Gill; Dalsu Baris; Adam Mumy; Demetrius Albanes; Mark P. Purdue; Amy Hutchinson; Alfredo Carrato; Adonina Tardón; Consol Serra; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R. Karagas; Alan R. Schned; W. Ryan Diver

Genome-wide association studies have identified a SNP, rs2294008, on 8q24.3 within the prostate stem cell antigen (PSCA) gene, as a risk factor for bladder cancer. To fine-map this region, we imputed 642 SNPs within 100 Kb of rs2294008 in addition to 33 markers genotyped in one of the reported genome-wide association study in 8,652 subjects. A multivariable logistic regression model adjusted for rs2294008 revealed a unique signal, rs2978974 (r2 = 0.02, D′ = 0.19 with rs2294008). In the combined analysis of 5,393 cases and 7,324 controls, we detected a per-allele odds ratio (OR) = 1.11 [95% confidence interval (CI) = 1.06–1.17, P = 5.8 × 10−5] for rs2294008 and OR = 1.07 (95% CI = 1.02–1.13, P = 9.7 × 10−3) for rs2978974. The effect was stronger in carriers of both risk variants (OR = 1.24, 95% CI = 1.08–1.41, P = 1.8 × 10−3) and there was a significant multiplicative interaction (P = 0.035) between these two SNPs, which requires replication in future studies. The T risk allele of rs2294008 was associated with increased PSCA mRNA expression in two sets of bladder tumor samples (n = 36, P = 0.0007 and n = 34, P = 0.0054) and in normal bladder samples (n = 35, P = 0.0155), but rs2978974 was not associated with PSCA expression. SNP rs2978974 is located 10 Kb upstream of rs2294008, within an alternative untranslated first exon of PSCA. The non-risk allele G of rs2978974 showed strong interaction with nuclear proteins from five cell lines tested, implying a regulatory function. In conclusion, a joint effect of two PSCA SNPs, rs2294008 and rs2978974, suggests that both variants may be important for bladder cancer susceptibility, possibly through different mechanisms that influence the control of mRNA expression and interaction with regulatory factors.


Occupational and Environmental Medicine | 2011

Occupation and bladder cancer in a population-based case–control study in Northern New England

Joanne S. Colt; Margaret R. Karagas; Molly Schwenn; Dalsu Baris; Alison Johnson; Patricia A. Stewart; Castine Verrill; Lee E. Moore; Jay H. Lubin; Mary H. Ward; Claudine Samanic; Nathaniel Rothman; Kenneth P. Cantor; Laura E. Beane Freeman; Alan R. Schned; Sai Cherala; Debra T. Silverman

Objectives We used data from a large, population-based case–control study in Maine, New Hampshire, and Vermont to examine relationships between occupation, industry and bladder cancer risk. Methods Lifetime occupational histories were obtained by personal interview from 1158 patients newly diagnosed with urothelial carcinoma of the bladder in 2001–2004, and from 1402 population controls. Unconditional logistic regression was used to calculate ORs and 95% CIs, adjusted for demographic factors, smoking and employment in other high-risk occupations. Results Male precision metalworkers and metalworking/plasticworking machine operators had significantly elevated risks and significant trends in risk with duration of employment (precision metalworkers: OR 2.2, 95% CI 1.4 to 3.4, ptrend=0.0065; metalworking/plasticworking machine operators: OR 1.6, 95% CI 1.01 to 2.6, ptrend=0.047). Other occupations/industries for which risk increased significantly with duration of employment included: for men, textile machine operators, mechanics/repairers, automobile mechanics, plumbers, computer systems analysts, information clerks, and landscape industry workers; for women, service occupations, health services, cleaning and building services, management-related occupations, electronic components manufacturing and transportation equipment manufacturing. Men reporting use of metalworking fluids (MWF) had a significantly elevated bladder cancer risk (OR 1.7, 95% CI 1.1 to 2.5). Conclusions Our findings support the hypothesis that some component(s) of MWF may be carcinogenic to the bladder. Our results also corroborate many other previously reported associations between bladder cancer risk and various occupations. More detailed analyses using information from the studys job-specific questionnaires may help to identify MWF components that may be carcinogenic, and other bladder carcinogens associated with a variety of occupations.


International Journal of Cancer | 2011

Hair dye use and risk of bladder cancer in the New England bladder cancer study.

Stella Koutros; Debra T. Silverman; Dalsu Baris; Shelia Hoar Zahm; Lindsay M. Morton; Joanne S. Colt; David W. Hein; Lee E. Moore; Alison Johnson; Molly Schwenn; Sai Cherala; Alan R. Schned; Mark A. Doll; Nathaniel Rothman; Margaret R. Karagas

Aromatic amine components in hair dyes and polymorphisms in genes that encode enzymes responsible for hair dye metabolism may be related to bladder cancer risk. We evaluated the association between hair dye use and bladder cancer risk and effect modification by N‐acetyltransferase‐1 (NAT1), NAT2, glutathione S‐transferase Mu‐1 (GSTM1) and glutathione S‐transferase theta‐1 (GSTT1) genotypes in a population‐based case–control study of 1193 incident cases and 1418 controls from Maine, Vermont and New Hampshire enrolled between 2001 and 2004. Individuals were interviewed in person using a computer‐assisted personal interview to assess hair dye use and information on potential confounders and effect modifiers. No overall association between age at first use, year of first use, type of product, color, duration or number of applications of hair dyes and bladder cancer among women or men was apparent, but increased risks were observed in certain subgroups. Women who used permanent dyes and had a college degree, a marker of socioeconomic status, had an increased risk of bladder cancer [odds ratio (OR) = 3.3, 95% confidence interval (CI): 1.2–8.9]. Among these women, we found an increased risk of bladder cancer among exclusive users of permanent hair dyes who had NAT2 slow acetylation phenotype (OR = 7.3, 95% CI: 1.6–32.6) compared to never users of dye with NAT2 rapid/intermediate acetylation phenotype. Although we found no relation between hair dye use and bladder cancer risk in women overall, we detected evidence of associations and gene‐environment interaction with permanent hair dye use; however, this was limited to educated women. These results need confirmation with larger numbers, requiring pooling data from multiple studies.


PLOS ONE | 2012

Large-Scale Pathway-Based Analysis of Bladder Cancer Genome-Wide Association Data from Five Studies of European Background

Idan Menashe; Jonine D. Figueroa; Montserrat Garcia-Closas; Nilanjan Chatterjee; Núria Malats; Antoni Picornell; Dennis Maeder; Qi Yang; Ludmila Prokunina-Olsson; Zhaoming Wang; Francisco X. Real; Kevin B. Jacobs; Dalsu Baris; Michael J. Thun; Demetrius Albanes; Mark P. Purdue; Manolis Kogevinas; Amy Hutchinson; Yi Ping Fu; Wei Tang; Laurie Burdette; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Alan R. Schned; Gerald L. Andriole

Pathway analysis of genome-wide association studies (GWAS) offer a unique opportunity to collectively evaluate genetic variants with effects that are too small to be detected individually. We applied a pathway analysis to a bladder cancer GWAS containing data from 3,532 cases and 5,120 controls of European background (n = 5 studies). Thirteen hundred and ninety-nine pathways were drawn from five publicly available resources (Biocarta, Kegg, NCI-PID, HumanCyc, and Reactome), and we constructed 22 additional candidate pathways previously hypothesized to be related to bladder cancer. In total, 1421 pathways, 5647 genes and ∼90,000 SNPs were included in our study. Logistic regression model adjusting for age, sex, study, DNA source, and smoking status was used to assess the marginal trend effect of SNPs on bladder cancer risk. Two complementary pathway-based methods (gene-set enrichment analysis [GSEA], and adapted rank-truncated product [ARTP]) were used to assess the enrichment of association signals within each pathway. Eighteen pathways were detected by either GSEA or ARTP at P≤0.01. To minimize false positives, we used the I2 statistic to identify SNPs displaying heterogeneous effects across the five studies. After removing these SNPs, seven pathways (‘Aromatic amine metabolism’ [PGSEA = 0.0100, PARTP = 0.0020], ‘NAD biosynthesis’ [PGSEA = 0.0018, PARTP = 0.0086], ‘NAD salvage’ [PARTP = 0.0068], ‘Clathrin derived vesicle budding’ [PARTP = 0.0018], ‘Lysosome vesicle biogenesis’ [PGSEA = 0.0023, PARTP<0.00012], ’Retrograde neurotrophin signaling’ [PGSEA = 0.00840], and ‘Mitotic metaphase/anaphase transition’ [PGSEA = 0.0040]) remained. These pathways seem to belong to three fundamental cellular processes (metabolic detoxification, mitosis, and clathrin-mediated vesicles). Identification of the aromatic amine metabolism pathway provides support for the ability of this approach to identify pathways with established relevance to bladder carcinogenesis.

Collaboration


Dive into the Molly Schwenn's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dalsu Baris

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Debra T. Silverman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joanne S. Colt

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nathaniel Rothman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Núria Malats

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge